As letermovir comes into clinical use in patients with refractory or resistant disease the development of resistance while on treatment has been observed, suggesting the need for close monitoring during treatment of active infection.
No takes yet. Share an insight, caveat, or question.
Veit et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: